# Yervoy® (ipilimumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ipilimumab

> Yervoy® (ipilimumab), sponsored by BRISTOL MYERS SQUIBB CO (BMY): 14 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Yervoy® (ipilimumab) |
| Codes |  |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications |  |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### March 10, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-108 (Efficacy): submission_status AP, submission_status_date 20200310, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### May 15, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-109 (Efficacy): submission_status AP, submission_status_date 20200515, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### May 26, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-110 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### September 18, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-112 (Efficacy): submission_status AP, submission_status_date 20200918, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### October 2, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-115 (Efficacy): submission_status AP, submission_status_date 20201002, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### May 25, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-121 (Efficacy): submission_status AP, submission_status_date 20210525, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### May 11, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-124 (Efficacy): submission_status AP, submission_status_date 20220511, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### May 27, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-122 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### February 15, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-129 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### September 26, 2024: FDA advisory committee meeting

- Status: completed. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will discuss the existing sBLAs which were approved for patients with previously untreated unresectable or metastatic esophageal squamous cell carcinoma: sBLA 125514/S-096 for KEYTRUDA (pembrolizumab) injection, submitted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; sBLAs 125554/S-105 and S-106 for OPDIVO (nivolumab) injection, submitted by Bristol Myers-Squibb Co.; and sBLA 125377/S-122 for YERVOY (ipilimumab) injection, submitted by Bristol Myers-Squibb Co." https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024

### January 28, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### April 8, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-135 (Efficacy): submission_status AP, submission_status_date 20250408, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22
- openFDA Drugs@FDA: "BLA125377 SUPPL-133 (Efficacy): submission_status AP, submission_status_date 20250411, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### May 23, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125377 SUPPL-136 (Efficacy): submission_status AP, submission_status_date 20250523, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-01-10, last confirmed 2026-05-06.
- SEC Form 10-K (accession 0001671927-26-000005): "We expect the Phase 3 trial to complete patient enrollment in the first half of 2026 with topline data expected as early as the second half of 2026." https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-006721): "Enrollment in the late-line cutaneous melanoma trial (TEBE-AM) remains on track for completion in the first half of this year with topline overall survival (OS) data as early as the second half of 2026." https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-019205): "The Company is currently enrolling patients in the TEBE-AM registrational Phase 3 trial and expects to complete enrollment in the first half of 2026 with topline data expected as early as the second half of 2026." https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/ef20072537_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-006721): "The Company is currently enrolling patients in the TEBE-AM registrational Phase 3 trial and expects to complete enrollment in the first half of 2026 with topline data expected as early as the second half of 2026." https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000837): "The Company is enrolling patients in three registrational Phase 3 trials, with the first topline results anticipated in 2026 and a potential to reach up to 15,000 additional patients across three new melanoma indications:" https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_ex99-1.htm
- SEC Form 10-K (accession 0001671927-26-000005): "In the first half of 2026, we expect to complete enrollment in the registrational, advanced melanoma trial, TEBE-AM, with topline data expected as early as the second half of 2026." https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ipilimumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Yervoy® (ipilimumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ipilimumab

```bibtex
@misc{secapidev_pdufa_ipilimumab_20261116,
  title        = {Yervoy® (ipilimumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ipilimumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ipilimumab_20261116","title":"Yervoy® (ipilimumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ipilimumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
